Reverse Distribution Designing a National Consumer Rx Returns Program

Reverse distribution designing a national consumer rx returns program l.jpg
1 / 33
0
0
951 days ago, 387 views
PowerPoint PPT Presentation
Plan. Diagram of pharmaceutical opposite distribution.National model for a shopper pharmaceutical returns program. Proposed changes in DEA regulations to empower such a project. . Reverse Distribution Overview. What is converse pharmaceutical distribution?Method for drug stores, healing centers, wholesalers, and so forth to return item for potential credit from the manufacturer.Product is portrayed by wa

Presentation Transcript

Slide 1

´╗┐Turn around Distribution & Designing a National Consumer Rx Returns Program October 23, 2006 Mary Hendrickson,RPh,MBA Director of Quality & Regulatory Affairs Capital Returns, Inc. Mary.Hendrickson@CapitalReturns.com

Slide 2

Agenda Overview of pharmaceutical invert appropriation. National model for a shopper pharmaceutical returns program. Proposed changes in DEA directions to empower such a program.

Slide 3

Reverse Distribution Overview What is turn around pharmaceutical appropriation? Technique for drug stores, healing facilities, wholesalers, and so on to return item for potential credit from the producer. Item is portrayed by waste stream and burned. Why do makers issue credit for terminated item? Makers need drug stores to stock item. Pharmaceutical item can be costly and have a short timeframe of realistic usability.

Slide 4

Manufacturers Distribution Creditable Product Reverse Distributors Wholesaler returns Wholesalers Direct records just Debit update data Waste Pharmacy Returns Reporting Incinerators Chains Hospitals Independents Retail/Institutional Pharmacies, LTC, Other aberrant client, and so on. Prepare Overview Rx Industry Distribution and Reverse Distribution Model

Slide 5

Reverse Distribution Rigorous turn around handling is essential: Environmental and administrative concerns: EPA FDA DEA DOT OSHA Why drug stores/producers outsource: Penalties for neglecting to meet directions Focus on center abilities.

Slide 6

Demographics of Reverse Distribution Major players have 85% of the market: Capital Returns, Inc. Stericycle Guaranteed Returns Carolina Logistics EXP Pharmaceutical Services Multiple littler invert merchants situated all through U.S.

Slide 7

Reverse Distribution Core Functionality Centralizes obsolete medications into a limited number of stockrooms which can be checked for administrative consistence. A large number of dollars came back to the medicinal services industry from pharmaceutical producers every year. Obsolete medications are expelled from the market in a controlled, orderly form bringing about diminished redirection potential outcomes. Strong framework set up for potential national shopper reclaim program.

Slide 8

Consumer Returns Currently no precise technique for buyers to discard pharmaceuticals . Expanded concentrate on effect of pharmaceutical waste on the earth . USGS Water Quality Study Warning: Side Effects Can Be Severe, Common medications are saturating our lakes, fish, and water supply. May 5, 2005 Milwaukee Journal/Sentinel Pharmaceuticals in Waterways Raise Concern: Effect on Wildlife, Humans Questioned. Washington Post, July 23, 2005.

Slide 9

Ideal National Consumer Drug Returns Program Easily available to all buyer Uses current foundation Tracks information NO PERSONAL DATA (HIPAA) Name, quality, dose shape Quantity Pharmacy of birthplace Manufacturer Funding Allocation to makers of returned items

Slide 10

Advantages of using converse conveyance for this procedure Limited number of complex players in the market that presently handle quiet level returns. Center competency is receipt, documentation, and legitimate transfer of obsolete medications. DEA registrants: have the procedure controls to guarantee item is not occupied and is legitimately arranged. Outsourcing of obsolete medication preparing by free retail, chain and mail-arrange drug stores moving toward 100%. Existing associations with pharma makers. Point of reference with DEA as of now exists in the administration of reviewed controlled substances.

Slide 11

Disadvantages of retail drug store beneficiaries Core competency is forward apportioning. Absence of comprehension and frameworks for safeguarding agreeable transfer. Capacity to be repaid for time/transfer might be risky. Drug specialist staffing as of now encountering extreme deficiencies Space for isolation and isolate not accessible. Open door for preoccupation significant. Sheriff or other law authorization required for receipt of controlled substances

Slide 12

Funding & Technical Challenges Pharma makers would need to support the cost of handling and transfer for their individual medication returns. RDs may need to re-design IT frameworks for this kind of information. Retail drug stores at all levels would need to take an interest and illuminate shoppers. Customers would need to endeavor.

Slide 13

Regulatory Challenges Drug Enforcement Administration US Environmental Protection Agency State Environmental Protection Agency DOT/USPS State Board of Pharmacy

Slide 14

Manufacturers Returns Data Reverse Distributors Wholesalers Waste Incinerators Chains ,MailOrder Independent Retail Pharmacies Process Overview Proposed Consumer Rx Returns Model Distribution Returns Dispense Distribution

Slide 15

A triumphant situation for everybody Responsible customers have an answer for the ecologically solid transfer of unused/undesirable remedies Diversion potential is reduced by expelling unused/undesirable prescription from homes. Makers would get beforehand inaccessible however amazingly profitable information on medication consistence and use Insurance organizations and other invested individuals could buy information on unused Rxs and create criticism circles for more noteworthy consistence and results investigation Reverse wholesalers give add up to shut circle handling to the pharma business.

Slide 16

Current DEA RD Regulations Definition and Registration of Reverse Distributors, May 2, 2005 Federal Register Amended Title 21, Code of Federal Regulations to characterize the expression "turn around dissemination" and set up another class of enrollment Impacted various existing directions

Slide 17

Relevant Supplementary Information* "The general objective of the Controlled Substances Act (CSA) and of DEA's controls in Title 21, Code of Federal Regulations (CFR), Parts 1300-1316, is to give a shut conveyance framework so that a controlled substance is at all circumstances under the lawful control of a man enlisted, or particularly exempted from enrollment, by the Drug Enforcement Administration until it achieves a definitive client or is decimated." *Federal Register, Vol. 70, No 83, May 2, 2005

Slide 18

Relevant Supplementary Information* "When a controlled substances has turned out to be obsolete or generally unusable, the registrant who has the substance must discard it. Be that as it may, over the previous decade, natural concerns and administrative changes have brought on medication makers and government organizations, (counting DEA and State specialists) to end up distinctly progressively hesitant to be required in the transfer procedure. Consequently, some transfer alternatives are no longer accessible." *Federal Register, Vol. 70, No 83, May 2, 2005

Slide 19

Relevant Supplementary Information* "For numerous years, DEA contradicted conceding DEA enlistments to firms exclusively or basically occupied with the transfer (regardless of whether the transportation divide, genuine transfer, or both) of controlled substances since they were not viewed as a fundamental connection in the shut dispersion framework that the Controlled Substances Act built up to control the stream of medications from the producers to a definitive client. As of late, however progressively stringent necessities forced by the U.S. Natural Protection Agency (EPA) brought about less and less affirmed transfer offices. *Federal Register, Vol. 70, No 83, May 2, 2005

Slide 20

Receipt from Non-Registrants Considered Primarily from long haul mind offices and related associations Rejected because of never again being "a piece of the shut arrangement of dispersion and are no longer subject to DEA's arrangement of comparing responsibility." Consumer comes back from living arrangements was not considered

Slide 21

Two Compelling Reasons to Re-Visit Decision Increasing concerns in regards to the effect of all pharmaceuticals, including controlled substances, on amphibian and different species Only suitable strategy for purchaser transfer is deplete or landfill (deferred contamination) Rising rates of preoccupation and unplanned poisonings and passings introduce an inadmissible general wellbeing hazard A steady, savvy, and secure return framework would limit these open doors

Slide 22

Precedent Already Established Reverse merchants occupied with maker reviews DEA has affirmed the receipt of the reviewed controlled substance down to the buyer level A shopper returns program financed by makers is basically a similar procedure just at the customer's tact

Slide 23

Expanding the Closed Loop Due the symptomatic alleviation gave by many controlled substances, for example, here and now torment help, many lawfully administered medicines are not totally devoured by the patient Bringing these undesirable meds over into a protected, controlled, condition has no drawback Insuring ecologically stable transfer strategies has just positive effects

Slide 24

DEA's Worst Case Because there is no real way to know precisely what number of measurements are being returned, RD workers could conceivably occupy inside the extent of their obligations Diversion by human services experts, drug store, and medication distributer representatives as of now jumps out at some degree notwithstanding all safeguards Security safety measures at experienced invert wholesalers squares with or surpasses those of retail drug stores and social insurance offices Removing "uncontrolled" controlled substances from families empowers in any event some level of responsibility for items

Slide 25

Proposed Data to be Collected Name and address of customer or operator (relative, companion) Name, quality, dose shape, and number of units of medication Manufacturer if conceivable

Slide 26

Proposed Logistics Dispensing drug store gives RD phone number and email and educates customer to contact RD if there should arise an occurrence of need to return solution (Note: this technique applies to all prescriptions, not simply controlled substances.) Upon receipt of demand, RD decides approximat

SPONSORS